ImmunoGen Financial Statements From 2010 to 2024
| IMGNDelisted Stock | USD 31.23 0.01 0.03% |
Check ImmunoGen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmunoGen main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . ImmunoGen financial statements analysis is a perfect complement when working with ImmunoGen Valuation or Volatility modules.
ImmunoGen |
ImmunoGen Company Profit Margin Analysis
ImmunoGen's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current ImmunoGen Profit Margin | (0.26) % |
Most of ImmunoGen's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmunoGen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, ImmunoGen has a Profit Margin of -0.2556%. This is 97.72% lower than that of the Biotechnology sector and 98.89% lower than that of the Health Care industry. The profit margin for all United States stocks is 79.87% lower than that of the firm.
ImmunoGen Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ImmunoGen's current stock value. Our valuation model uses many indicators to compare ImmunoGen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ImmunoGen competition to find correlations between indicators driving ImmunoGen's intrinsic value. More Info.ImmunoGen is rated third overall in return on equity category among related companies. It is rated third overall in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value ImmunoGen by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for ImmunoGen's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ImmunoGen's earnings, one of the primary drivers of an investment's value.About ImmunoGen Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ImmunoGen income statement, its balance sheet, and the statement of cash flows. ImmunoGen investors use historical funamental indicators, such as ImmunoGen's revenue or net income, to determine how well the company is positioned to perform in the future. Although ImmunoGen investors may use each financial statement separately, they are all related. The changes in ImmunoGen's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ImmunoGen's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ImmunoGen Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ImmunoGen. Please read more on our technical analysis and fundamental analysis pages.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate therapies to treat cancer. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Immunogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 106 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the ImmunoGen information on this page should be used as a complementary analysis to other ImmunoGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |